• PubMed
  • March 31, 2025
  • 2 views
Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation

N Engl J Med. 2025 Apr 10;392(14):1396-1405. doi: 10.1056/NEJMoa2500366. Epub 2025 Mar 29. ABSTRACT BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However,…

  • PubMed
  • March 31, 2025
  • 1 views
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes trial (TC4): a Bayesian pragmatic cluster randomized controlled trial

CMAJ. 2025 Mar 30;197(12):E309-E318. doi: 10.1503/cmaj.241862. ABSTRACT BACKGROUND: Dual antiplatelet therapy is the standard of care for acute coronary syndrome, but uncertainty exists regarding the optimal regimen for patients in…

  • PubMed
  • March 31, 2025
  • 2 views
Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation

N Engl J Med. 2025 Apr 10;392(14):1396-1405. doi: 10.1056/NEJMoa2500366. Epub 2025 Mar 29. ABSTRACT BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However,…

  • PubMed
  • March 31, 2025
  • 1 views
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes trial (TC4): a Bayesian pragmatic cluster randomized controlled trial

CMAJ. 2025 Mar 30;197(12):E309-E318. doi: 10.1503/cmaj.241862. ABSTRACT BACKGROUND: Dual antiplatelet therapy is the standard of care for acute coronary syndrome, but uncertainty exists regarding the optimal regimen for patients in…

  • PubMed
  • March 31, 2025
  • 1 views
Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation

N Engl J Med. 2025 Apr 10;392(14):1396-1405. doi: 10.1056/NEJMoa2500366. Epub 2025 Mar 29. ABSTRACT BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However,…

  • PubMed
  • March 31, 2025
  • 1 views
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes trial (TC4): a Bayesian pragmatic cluster randomized controlled trial

CMAJ. 2025 Mar 30;197(12):E309-E318. doi: 10.1503/cmaj.241862. ABSTRACT BACKGROUND: Dual antiplatelet therapy is the standard of care for acute coronary syndrome, but uncertainty exists regarding the optimal regimen for patients in…

  • PubMed
  • March 31, 2025
  • 1 views
Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation

N Engl J Med. 2025 Apr 10;392(14):1396-1405. doi: 10.1056/NEJMoa2500366. Epub 2025 Mar 29. ABSTRACT BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However,…

  • PubMed
  • March 31, 2025
  • 1 views
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes trial (TC4): a Bayesian pragmatic cluster randomized controlled trial

CMAJ. 2025 Mar 30;197(12):E309-E318. doi: 10.1503/cmaj.241862. ABSTRACT BACKGROUND: Dual antiplatelet therapy is the standard of care for acute coronary syndrome, but uncertainty exists regarding the optimal regimen for patients in…

  • PubMed
  • March 31, 2025
  • 1 views
Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation

N Engl J Med. 2025 Apr 10;392(14):1396-1405. doi: 10.1056/NEJMoa2500366. Epub 2025 Mar 29. ABSTRACT BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However,…

  • PubMed
  • March 31, 2025
  • 1 views
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes trial (TC4): a Bayesian pragmatic cluster randomized controlled trial

CMAJ. 2025 Mar 30;197(12):E309-E318. doi: 10.1503/cmaj.241862. ABSTRACT BACKGROUND: Dual antiplatelet therapy is the standard of care for acute coronary syndrome, but uncertainty exists regarding the optimal regimen for patients in…